Vaccine adjuvant and application thereof and porcine reproductive and respiratory syndrome vaccine

Abstract

The invention is applicable to the field of biomedicine, and provides a vaccine adjuvant and application thereof and a porcine reproductive and respiratory syndrome vaccine. The vaccine adjuvant is prepared from, by weight, 1-10 parts of a quillaja extract, 2-5 parts of a TLR3 receptor effector, 2000-5000 parts of diethylaminoethyl glucose and 1000-3000 parts of a stabilizer. The vaccine adjuvantis combined with a porcine reproductive and respiratory syndrome virus (PRRSV) inactivated antigen to increase the cellular immunity of a body, induce an interferon and reduce immunosuppression of PRRSV production. Thereof, a high content of a neutralizing antibody is produced more quickly, the maintenance time is long, the viremia of different strains can be reduced, and the safety and immune efficacy of the vaccine are enhanced.

Description

technical field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a vaccine adjuvant and its application and a porcine reproductive and respiratory syndrome vaccine. Background technique

[0002] Porcine reproductive and respiratory syndrome (PRRS, Porcine Reproductive and Respiratory Syndrome) is a highly contagious disease in pigs. The pathogen is porcine reproductive and respiratory syndrome virus. The main host of the virus is domestic pigs and wild boars in nature. . Pigs of different ages, breeds and genders can be infected with PRRSV (Porcine Reproductive and Respiratory Syndrome Virus), among which pregnant sows and suckling piglets are most likely to be infected. In addition to infecting animals, boar semen has also been identified as a common source of PRRSV infection.

[0003] The current common method of preventing and controlling PRRS is immunization and vaccination. Commonly used PRRS vaccines mainly include live attenuat...

Examples

Embodiment 1

[0026] A vaccine adjuvant comprising the following components: 1 mg of quillaja extract, 2 mg of TLR3 receptor effector (double-stranded RNA), 5 g of diethylaminoethyl glucose and 1 g of stabilizer (phosphate buffered saline).

[0027] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0028] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0029]Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 6.8.

Embodiment 2

[0031] A vaccine adjuvant comprising the following components: 10 mg of quillaja extract, 5 mg of TLR3 receptor effector (double-stranded RNA), 2 g of diethylaminoethyl glucose and 3 g of stabilizer (phosphate buffered saline).

[0032] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0033] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0034] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.8.

Embodiment 3

[0036] A vaccine adjuvant comprising the following components: 5 mg of quillaja extract, 3 mg of a TLR3 receptor effector (double-stranded RNA), 4 g of diethylaminoethyl glucose and 3 g of a stabilizer (phosphate buffered saline).

[0037] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0038] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0039] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.0.

technical field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a vaccine adjuvant and its application and a porcine reproductive and respiratory syndrome vaccine. Background technique

[0002] Porcine reproductive and respiratory syndrome (PRRS, Porcine Reproductive and Respiratory Syndrome) is a highly contagious disease in pigs. The pathogen is porcine reproductive and respiratory syndrome virus. The main host of the virus is domestic pigs and wild boars in nature. . Pigs of different ages, breeds and genders can be infected with PRRSV (Porcine Reproductive and Respiratory Syndrome Virus), among which pregnant sows and suckling piglets are most likely to be infected. In addition to infecting animals, boar semen has also been identified as a common source of PRRSV infection.

[0003] The current common method of preventing and controlling PRRS is immunization and vaccination. Commonly used PRRS vaccines mainly include live attenuat...

Examples

Embodiment 1

[0026] A vaccine adjuvant comprising the following components: 1 mg of quillaja extract, 2 mg of TLR3 receptor effector (double-stranded RNA), 5 g of diethylaminoethyl glucose and 1 g of stabilizer (phosphate buffered saline).

[0027] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0028] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0029]Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 6.8.

Embodiment 2

[0031] A vaccine adjuvant comprising the following components: 10 mg of quillaja extract, 5 mg of TLR3 receptor effector (double-stranded RNA), 2 g of diethylaminoethyl glucose and 3 g of stabilizer (phosphate buffered saline).

[0032] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0033] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0034] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.8.

Embodiment 3

[0036] A vaccine adjuvant comprising the following components: 5 mg of quillaja extract, 3 mg of a TLR3 receptor effector (double-stranded RNA), 4 g of diethylaminoethyl glucose and 3 g of a stabilizer (phosphate buffered saline).

[0037] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0038] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0039] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.0.

Images